On September 10, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported that updated monotherapy clinical data from the ongoing Phase 1 AURORAS-1 trial of ERAS-0015 will be shared in an oral presentation and nonclinical combination data of ERAS-0015 and ERAS-4001 will be shared in a poster presentation at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) (ENA) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20 in Barcelona, Spain. ERAS-0015 is a potential best-in-class pan-RAS molecular glue in development for the treatment of patients with RAS-mutant solid tumors. ERAS-4001 is a potential first-in-class and best-in-class pan-KRAS inhibitor in development for the treatment of patients with KRAS-mutant solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing an expanded AURORAS-1 monotherapy dataset with the medical community at the ENA Symposium, including results from more patients and with longer follow-up," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "The clinical activity and favorable tolerability observed in our prior data disclosures underscore the potential of ERAS-0015 to meaningfully improve outcomes for patients with RAS-mutant cancers. We’re also excited to share nonclinical data for the combination of ERAS-0015 and ERAS-4001 showing synergy in KRAS G12X-driven models. With strong momentum across the pipeline, we are rapidly advancing toward three potentially registration-enabling trials for ERAS-0015 in pancreatic and lung cancers."

Oral Presentation Details

Title: Preliminary safety, pharmacokinetics, and efficacy of ERAS-0015: Results from the AURORAS-1 first-in-human trial
Speaker: Judy Wang, M.D., Florida Cancer Specialists, Sarah Cannon Research Institute
Date and Time: Friday, November 20, 12:30 p.m. Central European Time
Session: Plenary Session 6, Proferred Papers
Location: Room 111 + 112

Poster Presentation Details

Title: Combination of ERAS-0015 and ERAS-4001 targets active and inactive KRAS and displays synergy in nonclinical KRAS G12X-driven models
Presenter: Erin Lew, Ph.D., Erasca, Inc.
Date and Time: Friday, November 20, 9:00 a.m. – 3:00 p.m. Central European Time
Session: Combination Therapies
Location: Exhibition Hall

About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability results, well-behaved, linear PK, and confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed partial responses at doses as low as 8 mg once daily (QD). ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species.

About ERAS-4001
ERAS-4001 is an investigational, oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. ERAS-4001 demonstrated favorable preclinical in vitro potency against KRAS G12X mutations as well as KRAS wildtype amplifications, which may limit treatment resistance mediated through KRAS wildtype activation. No activity was observed for ERAS-4001 against HRAS or NRAS wildtype proteins in preclinical studies, which may enable a better therapeutic window compared to pan-RAS inhibitors. ERAS-4001 showed potent activity against both GTP-bound (active state) and GDP-bound (inactive state) KRAS with single digit nanomolar IC50s. In vivo, ERAS-4001 induced tumor regression in multiple KRAS-mutant models. In preclinical studies, ERAS-4001 showed encouraging ADME and PK properties.

(Press release, Erasca, SEP 10, 2026, View Source [SID1234670742])

On September 10, 2026 MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, reported its presentation of a poster featuring its second-generation telomere-targeting anticancer drug candidates at the recent XXVI International Round Table on Nucleosides, Nucleotides and Nucleic Acids (IRT 2026) held in Barcelona, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MAIA’s lead drug candidate, ateganosine, is a first-in-class telomere-targeting therapy designed to selectively damage cancer-cell telomeres while activating the body’s antitumor immune response. The poster and oral presentations highlighted both ateganosine’s novel mechanism of action and MAIA’s next-generation divalent telomere-targeting drug candidates, which combine ateganosine with a complementary DNA-targeting agent in a single prodrug molecule. These next-generation candidates are designed to attack tumors through multiple mechanisms, with the goal of delivering greater efficacy than ateganosine alone.

"Our presentations at IRT 2026 reflect the continued scientific progress of our telomere-targeting platform and significant scientific interest in our research," said Vlad Vitoc, M.D., Founder and CEO of MAIA. "Our next-generation program is designed to expand the therapeutic potential and versatility of our science and support our long-term strategy of developing differentiated therapies that address significant unmet medical needs."

"It was an honor to participate at IRT 2026, where we shared how we are advancing our telomere-targeting platform with next-generation prodrug molecules designed to enhance antitumor activity," said Sergei Gryaznov, Ph.D., Chief Scientific Officer of MAIA. "By evaluating multiple molecular designs in complementary cell-based studies and preclinical in vivo tumor models, we have identified structural features associated with the strongest antitumor activity. These findings are helping us optimize our next-generation therapies while further validating the potential of our platform to induce durable antitumor immune responses."

"IRT 2026 provided an important opportunity to share the progress of our next-generation telomere-targeting programs with leading researchers in the field and to discuss how these advances could translate into new therapeutic approaches for cancer," said Victor Zaporojan, M.D., Executive Medical Director of MAIA Biotechnology. "The data presented at the conference demonstrate the breadth of our platform beyond ateganosine and reinforce our strategy of developing increasingly potent and optimized molecules that leverage telomere biology to selectively target cancer cells. We believe this work further strengthens the scientific foundation for expanding MAIA’s pipeline across multiple tumor types."

MAIA’s presentations:

Oral: "Novel Divalent Cancer RedOx Activatable Nucleoside Prodrugs as Potent Anticancer Modalities"
Poster: "New Telomere-Targeting Dual-Pharmacophore Dinucleotide Prodrugs for Anticancer Therapy"
MAIA was a sponsor of IRT 2026. MAIA’s IRT 2026 poster is available at maiabiotech.com/publications.

About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

(Press release, MAIA Biotechnology, SEP 10, 2026, View Source [SID1234670741])

On September 10, 2026 Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, reported that it will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC), being held September 12-15, 2026 in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously announced, the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC) met its primary endpoint of progression-free survival at a planned interim analysis.

Virtual Event Details

Cullinan Therapeutics will host a virtual event for analysts and institutional investors on Monday, September 14, 2026, at 8:00 a.m. ET, following the Presidential Symposium presentation. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, Jeffrey Jones, MD, MBA, Chief Medical Officer.

A live webcast will be available via the events page of Cullinan Therapeutics’ investor relations website at View Source A replay will be archived on the website following the event.

(Press release, Cullinan Oncology, SEP 10, 2026, View Source [SID1234670740])

On September 10, 2026 One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, reported support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across millions of cells, masking the tumor heterogeneity that drives resistance and treatment failure.

The CAST project, led by One Biosciences in partnership with Institut Curie, aims to overcome these limitations. This four-year program seeks to bring OneMap, One Biosciences’ cutting-edge solution, to market as the first single-cell diagnostic platform designed to guide treatment decisions for patients with TNBC, commercialized as an in vitro diagnostic test.

OneMap combines single-cell transcriptomics and AI to analyze tumors at the resolution of individual cells and deliver clinically actionable reports within two weeks directly from standard hospital biopsies. By deciphering tumor heterogeneity at single-cell resolution and identifying the specific cell populations that may drive treatment resistance, this platform could enable clinicians to make more informed treatment decisions for each patient.

Initial studies conducted jointly by One Biosciences and Institut Curie have already demonstrated the ability to generate high-quality single-cell data from routine TNBC biopsies and identify cellular signatures associated with response to immunotherapy. CAST will further build on Institut Curie’s unique clinical expertise and its Institute of Women’s Cancers, co-founded with PSL university and INSERM, providing access to a cohort of more than 300 TNBC patients. This project is expected to become the world’s largest clinically annotated single-cell dataset in triple-negative breast cancer.

Supported by €3.3 million in funding under the fifth 2026 i-Démo call for projects as part of the France 2030 initiative, the CAST program will focus on four key areas: industrializing the OneMap platform, validating predictive biomarkers in TNBC, preparing for regulatory approval, and scaling One Biosciences’ centralized clinical laboratory infrastructure in the Paris region to enable future commercial deployment.

"This funding is a defining milestone for One Biosciences and the progression of single cell technology into the clinic," said Hedi Ben Brahim, CEO of One Biosciences. "CAST accelerates the path from breakthrough science to a scalable commercial product that can help oncologists make better treatment decisions for patients. We are very grateful to France 2030 for their transforming support."

"CAST perfectly reflects Institut Curie’s mission: transforming cutting-edge research into tangible benefits for patients," said Dr. Céline Vallot, Co-founder & Chief Scientific Officer of One Biosciences, CNRS Research Director, and head of the Dynamics of Epigenetic Plasticity in Cancer team2 at Institut Curie. "By bringing single-cell technologies into clinical practice, we have the opportunity to fundamentally improve the treatment of aggressive cancers. This approach helps ensure that every patient receives the treatment best suited to the unique biology of their disease, ultimately improving outcome and quality of life."

"Triple-negative breast cancer remains one of the hardest breast cancers to treat because we still lack robust tools to predict response and resistance," added Dr. Luc Cabel, medical oncologist at Institut Curie and Principal Investigator of the CAST project. "The medical need is to deescalate treatment for good responders to limit the side effects and to better chose a salvage treatment for bad responders. By combining clinical expertise with single-cell and AI technologies, CAST has the potential to give oncologists a much more precise understanding of each patient’s tumor and ultimately improve treatment decisions and outcomes."

By bridging the gap between research and clinical deployment, the CAST project represents a major step toward making single-cell precision oncology a reality for patients.

(Press release, One Biosciences, SEP 10, 2026, View Source [SID1234670739])

On September 10, 2026 OncoHost, a technology company transforming precision oncology through proteomics-based biomarker development, reported its acceptance to present a scientific poster at the 2026 World Conference on Lung Cancer (WCLC), taking place September 12–15, 2026, in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC," evaluates whether PROphetNSCLC maintains its predictive performance when blood samples are collected beyond the traditional pre-treatment time point.

PROphetNSCLC is a plasma proteomics-based test designed to guide immune checkpoint inhibitor (ICI) treatment decision-making in advanced non-small cell lung cancer (NSCLC). While PROphetNSCLC was developed using samples collected prior to initiation of ICI treatment, real-world clinical workflows may not always allow for baseline blood collection. The study therefore assessed the stability of the plasma proteome and the concordance of PROphetNSCLC result in different sampling time points.

"The PROphet plasma proteomic assay has proven clinical utility as a baseline in treatment naïve patients, but in practice some patients don’t have pre-treatment samples" said Dr. David Gandara, Medical Oncologist & clinical-translational researcher in lung cancer, Co-Director-Center for Experimental Therapeutics, UC Davis Comprehensive Cancer Center, Clinical Advisor at OncoHost and co-author of the study. "These new data that PROphet results remain stable even after a patient begins chemotherapy or immunotherapy reinforce the reliability and clinical applicability of the assay".

"Immunotherapy is today the cornerstone of treatment for NSCLC patients without an oncogenic driving abnormality", added Fred Hirsch, MD, PhD, FASCO, Professor of Medicine & Pathology, Medical Oncologist, Clinical Advisor at OncoHost and co-author of the study. "The PROphet blood-based assay has demonstrated in several studies it can predict which patients who will benefit from immunotherapy with or without chemotherapy or not. The presented study shows the predictive stability of the test even if it is sampled during treatment, which makes the test very usable in the real-world setting".

The analysis included plasma samples collected from patients with advanced NSCLC receiving ICI-based therapies at three time points: prior to treatment; following one cycle of chemotherapy but before initiation of ICI therapy; and following one cycle of ICI-based treatment. Proteomic profiling measured 7,289 proteins, while investigators evaluated changes across the plasma proteome, preservation of Resistance Associated Protein (RAP; the PROphetNSCLC model proteins) expression, and the consistency of PROphet classification.

Results demonstrated substantial preservation of the biological signal underlying PROphetNSCLC despite treatment initiation. Among matched samples collected at baseline and following one cycle of chemotherapy, only 20 of the 7,289 measured proteins were differentially expressed, with none belonging to the 388 RAPs used by PROphet. Greater proteomic changes were observed following one cycle of ICI-based treatment, with 888 differentially expressed proteins, including 81 RAPs. Despite these changes, more than 73% of RAPs remained strongly correlated between matched samples across both longitudinal comparisons.

Comparison between the plasma proteome at baseline and after 1 chemotherapy or ICI-based cycle showed that more than 73% of the RAPs remained strongly correlated between matched samples. In concordance with the RAP preservation, PROphet classification demonstrated high consistency between matched samples, reaching 80% following chemotherapy and 69% following one cycle of ICI-based treatment, with no significant systematic bias compared with baseline classification. Importantly, PROphet maintained significant separation in overall survival between PROphet-POSITIVE and PROphet-NEGATIVE patients following one cycle of ICI-based treatment (HR=0.54, p=0.009).

"These findings represent an important step in expanding the real-world clinical utility of PROphetNSCLC," said Ofer Sharon, M.D., CEO of OncoHost. "Our goal is to ensure that more patients can benefit from precision treatment guidance, even when the realities of clinical care may require treatment to begin before all biomarker results are available. Demonstrating that PROphet maintains its predictive performance following one cycle of chemotherapy broadens the patient population for whom the test may be relevant and reinforces our commitment to delivering precision oncology solutions that integrate seamlessly into real-world clinical practice."

Poster Presentation Details
Title: PROphetNSCLC Maintains Predictive Performance in Longitudinal Sampling Beyond Baseline in Metastatic NSCLC
Poster Board #: P2.188
Presenters: David R. Gandara, M.D. & Fred Hirsch, M.D., co-authors of the study
Date & Time: 14/09/26 10:30-12:00 PM KST.

(Press release, OncoHost, SEP 10, 2026, View Source [SID1234670738])